Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00344292 · ClinicalTrials.gov registry record

Understanding the Genetic and Hereditary Basis of Atherosclerosis

A clinical trial of Cardiovascular Diseases and Atherosclerosis, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
2,763
Enrollment target
4
Study locations

NCT00344292: Completed study of Cardiovascular Diseases and Atherosclerosis, sponsored by Wake Forest University Health Sciences.

NCT00344292 is a study of Cardiovascular Diseases and Atherosclerosis that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 2,763 participants, below the 26,965-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00344292, a study of Cardiovascular Diseases and Atherosclerosis, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
2,763 participants
Enrollment target
4
Study locations

Study Summary

Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible for the development of atherosclerosis.

Study Locations (4)

California

  • Cedars-Sinai Health System - Los Angeles

Louisiana

  • Louisiana State University - New Orleans

Texas

  • The University of Texas - Houston

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 2,763 participants
Start Date 2006-03
Est. Completion 2012-02
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT00344292 record still lists

NCT00344292 is an observational study that tracks outcomes without assigning an intervention. Its 2,763 participants enrollment target places it among the larger protocols in the corpus, below the 26,965-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT00344292 reports a single indexed study location in California, Louisiana, Texas.

Frequently Asked Questions

What is clinical trial NCT00344292 about?

NCT00344292 is a clinical study titled "Understanding the Genetic and Hereditary Basis of Atherosclerosis". Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible...

What is the current status of trial NCT00344292?

This trial is currently completed. The enrollment target is 2,763 participants. The study started on 2006-03. Estimated completion is 2012-02.

What conditions does trial NCT00344292 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Atherosclerosis.

Who is sponsoring clinical trial NCT00344292?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00344292 being conducted?

This trial has 4 study locations across California, Louisiana, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00344292's enrollment target sits among peer trials

2,763 31st of 300 higher than 270 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05443737 · 2,800 participants · Phase 3

    Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

  • NCT05899439 · 2,800 participants

    Immune Function and the Progression to T1D

  • NCT06089109 · 2,800 participants · NA

    Creating VIP Corps to Reduce Maternal Deaths

  • NCT06345339 · 2,800 participants · Phase 2

    A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00344292, the US trial registry maintained by the National Library of Medicine. NCT00344292 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.